Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

S Peters, R Camidge, R Dziadziuszko, S Gadgeel, A T Shaw, D-W Kim, M Pérol, D R Rosell, P Cheema, D Wan-Teck Lim, J J Lin, N Pavlakis, J S Ahn, L Zhang, V Henschel